Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Ceases Development of TAK-700 for Prostate Cancer on Lackluster PIII Results
June 20, 2014
- Takeda Launches Zacras Combination Tablets
June 20, 2014
- DSP Now Renamed “Sumitomo Dainippon Pharma” in English
June 19, 2014
- Serious ADRs Reported in Xeljanz EPPV Include Heart Failure, Pneumonia: Prof.
June 19, 2014
- Novartis Begins Global Filings for PV Treatment Ruxolitinib following Positive PIII Results
June 19, 2014
- Ono Calls Off License Pact with German Peer Merck for ONO-4641
June 19, 2014
- Japan Vaccine President and Chairman Swap Posts
June 19, 2014
- Fycompa Meets Primary Endpoints in Patients with PGTC Seizures in PIII Study: Eisai
June 19, 2014
- Takeda UC, CD Treatment Entyvio Goes on Sale in US
June 18, 2014
- Selexipag Meets Primary Endpoint in PIII GRIPHON Study: Nippon Shinyaku
June 18, 2014
- Canagliflozin Shows Significant Improvement in Glycemic Control against Placebo in PIII Study: MTPC
June 18, 2014
- Sawai Seeks US Approval for Livalo Generic, Submits ANDA
June 17, 2014
- Takeda to Withdraw US NDA for Anemia Drug, Cancel Deal with Affymax
June 17, 2014
- Meiji Seika Pharma, Fresenius Kabi Japan Terminate Alliance for Generic Drugs
June 17, 2014
- AZ to Shuffle Sales, Marketing Units, Focus on 3 Disease Areas
June 16, 2014
- Meiji Seika Pharma to Acquire Indian Generic Drug Maker Medreich for US$290 Million
June 16, 2014
- Ex-Novartis Employee Suspected of Manipulating the Number of Events in Sub-Analysis
June 13, 2014
- Teijin Now Largest Shareholder of Kyorin Holdings, Owns 19.12% Stake
June 13, 2014
- Takeda Debuts Aspirin-PPI Combination Drug Takelda in Japan
June 13, 2014
- Valeant Wins US Approval for Kaken’s Onychomycosis Drug
June 12, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…